Search research articles
Contact Us
Filters
Showing results (61-70 of 84) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jennifer A Woyach, Lugui Qiu, Sebastian Grosicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Blood Advances
|
August 26, 2020
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
Lindsey E Roeker, Peter Dreger, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)
Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Blood Advances
|
August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study
Nirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2018
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays
Catherine C Coombs, Nancy K Gillis, Xianming Tan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 19, 2023
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study
Mazyar Shadman, Beenish S Manzoor, Kavita Sail, et al.
Haematologica
|
February 22, 2020
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia
Toby A Eyre, Nicole Lamanna, Lindsey E Roeker, et al.
American Journal of Hematology
|
December 19, 2024
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study
Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 84) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jennifer A Woyach, Lugui Qiu, Sebastian Grosicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Blood Advances
|
August 26, 2020
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
Lindsey E Roeker, Peter Dreger, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)
Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Blood Advances
|
August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study
Nirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2018
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays
Catherine C Coombs, Nancy K Gillis, Xianming Tan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 19, 2023
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study
Mazyar Shadman, Beenish S Manzoor, Kavita Sail, et al.
Haematologica
|
February 22, 2020
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia
Toby A Eyre, Nicole Lamanna, Lindsey E Roeker, et al.
American Journal of Hematology
|
December 19, 2024
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study
Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, et al.
Page
of 9